Product name: oseltamivir phosphate
Chemical name: (3 r, 4 r, 5 s) - 4 - ethyl amide group - amino - 3-5 - (1 -) ethyl propyl oxygen radicals - 1 - cyclohexene - 1 - carboxylic acid ethyl ester phosphate Oseltamivir phosphate;
Baton rouge (3 r, 4 r, 5 s) - 4 - acetamido - 5 - amino - 3 - pentan - 3-1 - carboxylate yloxycyclohexene - phosphate
MF: C16H28N2O4.H3PO4
NW: 410.40
Appearance: white to yellowish-white powder
CAS No: 204255-11-8
*The following content is generated by AI and is for reference only.
Oseltamivir phosphate, widely recognized by its brand name Tamiflu, is a potent antiviral medication primarily utilized for the prevention and treatment of influenza A and B infections. Chemically known as Oseltamivir phosphate, this prodrug possesses the molecular formula C16H31N2O8P and is identified by the CAS number 196170-74-4. It serves as an ethyl ester prodrug of oseltamivir carboxylate, which is the active metabolite responsible for inhibiting the viral neuraminidase enzyme. By blocking this enzyme, the drug prevents the release of newly formed viral particles from infected cells, thereby limiting the spread of the virus within the host respiratory tract.
The clinical utility of Oseltamivir phosphate is most effective when administered within 48 hours of symptom onset in patients with confirmed or suspected influenza. Its application extends to both therapeutic treatment for symptomatic individuals and prophylactic use for high-risk populations exposed to the virus, such as during seasonal outbreaks or pandemic events. The formulation is available in various dosage forms, including capsules, oral suspension powder, and pre-mixed liquids, making it accessible for diverse patient demographics ranging from pediatric to geriatric groups. While generally well-tolerated, common side effects may include nausea, vomiting, and headache, though serious adverse reactions are rare.
This medication represents a cornerstone in global public health strategies against influenza, significantly reducing the duration of symptoms, preventing complications like pneumonia, and lowering hospitalization rates. Its mechanism of action remains specific to orthomyxoviruses, distinguishing it from broad-spectrum antibiotics. As influenza viruses continue to evolve, Oseltamivir phosphate remains a critical tool in medical arsenals, often recommended by major health organizations like the WHO and CDC for managing seasonal flu risks. Continuous monitoring of resistance patterns ensures its continued efficacy in controlling viral transmission worldwide.